Carbamazepine (All indications) updated on 04-22-2025

Pulmonary valve stenosis

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19320
R81874		 Kim (Controls exposed to LTG) (Carbamazepine) (Indications NOS), 2026 Pulmonary valve stenosis 1st trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.68 [0.10;26.98] C
excluded (control group) 		1/427   1/718 2 427
ref
S19312
R81766		 Kim (Controls unexposed, NOS) (Carbamazepine) (Indications NOS), 2026 Pulmonary valve stenosis 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.44 [0.20;10.26] 1/427   4,047/2,489,078 4,048 427
ref
Total 1 studies 1.44 [0.20;10.31] 4,048 427
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kim (Controls unexposed, NOS) (Carbamazepine) (Indications NOS), 2026Kim, 2026 1 1.44[0.20; 10.26]4,0484270%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate0.55.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS) (Carbamazepine) (Indications NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.44[0.20; 10.31]4,048427 -NAKim (Controls unexposed, NOS) (Carbamazepine) (Indications NOS), 2026 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.44[0.20; 10.31]4,048427 -NAKim (Controls unexposed, NOS) (Carbamazepine) (Indications NOS), 2026 1 Tags Adjustment   - Yes  - Yes 1.44[0.20; 10.31]4,048427 -NAKim (Controls unexposed, NOS) (Carbamazepine) (Indications NOS), 2026 1 All studiesAll studies 1.44[0.20; 10.31]4,048427 -NAKim (Controls unexposed, NOS) (Carbamazepine) (Indications NOS), 2026 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 19320

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.44[0.20; 10.31]4,048427 -NAKim (Controls unexposed, NOS) (Carbamazepine) (Indications NOS), 2026 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.68[0.10; 26.98]2427 -NAKim (Controls exposed to LTG) (Carbamazepine) (Indications NOS), 2026 10.510.01.0